{"id":"W4416019198","doi":"10.1016/j.ijgc.2025.102156","title":"PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-826","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Bevacizumab; Pembrolizumab; Chemotherapy; Cervical cancer; Monoclonal","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001584784,0.0004111798,0.0008431994,0.0003127971,0.0004303989,0.0007460724,0.0005750749,0.00100227,0.003999353],"category_scores_gemma":[0.002717263,0.0003453422,0.002299297,0.0005216597,0.0002526618,0.001005439,0.0005264445,0.001670037,0.0005713266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000528629,"about_ca_system_score_gemma":0.001037472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006225147,"about_ca_topic_score_gemma":0.01038965,"domain_scores_codex":[0.9993987,0.0001658081,0.00004580723,0.0001746756,0.00007640733,0.0001386719],"domain_scores_gemma":[0.9991037,0.0002447259,0.0003256277,0.00006803529,0.00008826606,0.0001696304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.685625,0.009927021,0.1953361,0.0023971,0.0148643,0.0001428474,0.0004909859,0.0005320275,0.003870514,0.0001915627,0.006284409,0.08033826],"study_design_scores_gemma":[0.1072571,0.0930458,0.7631025,0.0009319801,0.02566824,0.0001800477,0.0008911553,0.0007603706,0.001425324,0.0004671661,0.006175338,0.00009499263],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990449,0.003558487,0.0001703961,0.000203409,0.0001329262,0.0003322313,0.003703811,0.00002126336,0.00142843],"genre_scores_gemma":[0.9926886,0.00156807,0.000264776,0.0004084584,0.00008102458,0.000528647,0.00254283,0.000007851489,0.001909773],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006225147,"threshold_uncertainty_score":0.01337916,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.103389803524005,"score_gpt":0.4244518838935613,"score_spread":0.3210620803695563,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}